Supernus Pharmaceuticals, Inc. (SUPN) NASDAQ
51.28
+2.0552(+4.18%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
51.28
+2.0552(+4.18%)
Currency In USD
| Previous Close | 49.22 |
| Open | 49.79 |
| Day High | 52.31 |
| Day Low | 49.61 |
| 52-Week High | 59.68 |
| 52-Week Low | 29.16 |
| Volume | 272,849.71 |
| Average Volume | 716,527 |
| Market Cap | 2.95B |
| PE | -75.4 |
| EPS | -0.68 |
| Moving Average 50 Days | 51.35 |
| Moving Average 200 Days | 46.76 |
| Change | 2.06 |
Supernus Pharmaceuticals to Participate in March Investor Conferences
GlobeNewswire Inc.
Feb 23, 2026 11:15 PM GMT
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
GlobeNewswire Inc.
Feb 12, 2026 9:35 PM GMT
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announ
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
GlobeNewswire Inc.
Dec 03, 2025 9:05 PM GMT
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced to